Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers

An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and... ORIGINAL ARTICLE An Integrated Prognostic Classifier for Stage I Lung   Adenocarcinoma Based on mRNA, microRNA,  and DNA Methylation Biomarkers Ana I. Robles, PhD,* Eri Arai, MD,† Ewy A. Mathé, PhD*, Hirokazu Okayama, MD, PhD,* Aaron J. Schetter, PhD, MPH,* Derek Brown, MS,* David Petersen, BS,‡ Elise D. Bowman, MS,* Rintaro Noro, MD,* Judith A. Welsh, BS,* Daniel C. Edelman, PhD,‡ Holly S. Stevenson, PhD,‡ Yonghong Wang, PhD,‡ Naoto Tsuchiya, PhD,§ Takashi Kohno, PhD,§ Vidar Skaug, MD,║ Steen Mollerup, MD,║ Aage Haugen, MD,║ Paul S. Meltzer, MD, PhD,‡ Jun Yokota, MD,¶ Yae Kanai, MD, PhD,† and Curtis C. Harris, MD* identified high-risk patients in stratified analysis of stages IA and Introduction: Up to 30% stage I lung cancer patients suffer recur- IB. Four protein-coding gene (XPO1, BRCA1, HIF1α, and DLC1), rence within 5 years of curative surgery. We sought to improve miR-21 expression, and HOXA9 promoter methylation were each existing protein-coding gene and microRNA expression prognostic independently associated with outcome (HR, 2.8; p = 0.002; HR, 2.3; classifiers by incorporating epigenetic biomarkers. p = 0.01; and HR, 2.4; p = 0.005, respectively), and when com- Methods: Genome-wide screening of DNA methylation and pyrose- bined, identified high-risk, therapy naive, stage I patients (HR, 10.2; quencing analysis of HOXA9 promoter methylation were performed in p http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers

Harris, Curtis C.
Journal of Thoracic Oncology , Volume 10 (7) – Jul 1, 2015
Download PDF
12 pages

Loading next page...
 
/lp/wolters-kluwer-health/an-integrated-prognostic-classifier-for-stage-i-lung-adenocarcinoma-an8yKGzXOC

References (48)

Copyright
Copyright © 2015 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000560
pmid
26134223
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE An Integrated Prognostic Classifier for Stage I Lung   Adenocarcinoma Based on mRNA, microRNA,  and DNA Methylation Biomarkers Ana I. Robles, PhD,* Eri Arai, MD,† Ewy A. Mathé, PhD*, Hirokazu Okayama, MD, PhD,* Aaron J. Schetter, PhD, MPH,* Derek Brown, MS,* David Petersen, BS,‡ Elise D. Bowman, MS,* Rintaro Noro, MD,* Judith A. Welsh, BS,* Daniel C. Edelman, PhD,‡ Holly S. Stevenson, PhD,‡ Yonghong Wang, PhD,‡ Naoto Tsuchiya, PhD,§ Takashi Kohno, PhD,§ Vidar Skaug, MD,║ Steen Mollerup, MD,║ Aage Haugen, MD,║ Paul S. Meltzer, MD, PhD,‡ Jun Yokota, MD,¶ Yae Kanai, MD, PhD,† and Curtis C. Harris, MD* identified high-risk patients in stratified analysis of stages IA and Introduction: Up to 30% stage I lung cancer patients suffer recur- IB. Four protein-coding gene (XPO1, BRCA1, HIF1α, and DLC1), rence within 5 years of curative surgery. We sought to improve miR-21 expression, and HOXA9 promoter methylation were each existing protein-coding gene and microRNA expression prognostic independently associated with outcome (HR, 2.8; p = 0.002; HR, 2.3; classifiers by incorporating epigenetic biomarkers. p = 0.01; and HR, 2.4; p = 0.005, respectively), and when com- Methods: Genome-wide screening of DNA methylation and pyrose- bined, identified high-risk, therapy naive, stage I patients (HR, 10.2; quencing analysis of HOXA9 promoter methylation were performed in p

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jul 1, 2015

There are no references for this article.